223 related articles for article (PubMed ID: 17148659)
1. Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts.
Monis GF; Schultz C; Ren R; Eberhard J; Costello C; Connors L; Skinner M; Trinkaus-Randall V
Am J Pathol; 2006 Dec; 169(6):1939-52. PubMed ID: 17148659
[TBL] [Abstract][Full Text] [Related]
2. Cellular response of cardiac fibroblasts to amyloidogenic light chains.
Trinkaus-Randall V; Walsh MT; Steeves S; Monis G; Connors LH; Skinner M
Am J Pathol; 2005 Jan; 166(1):197-208. PubMed ID: 15632012
[TBL] [Abstract][Full Text] [Related]
3. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.
Marin-Argany M; Lin Y; Misra P; Williams A; Wall JS; Howell KG; Elsbernd LR; McClure M; Ramirez-Alvarado M
J Biol Chem; 2016 Sep; 291(38):19813-25. PubMed ID: 27462073
[TBL] [Abstract][Full Text] [Related]
4. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
5. Role of mutations in the cellular internalization of amyloidogenic light chains into cardiomyocytes.
Levinson RT; Olatoye OO; Randles EG; Howell KG; DiCostanzo AC; Ramirez-Alvarado M
Sci Rep; 2013; 3():1278. PubMed ID: 23417147
[TBL] [Abstract][Full Text] [Related]
6. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
7. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
Imperlini E; Gnecchi M; Rognoni P; Sabidò E; Ciuffreda MC; Palladini G; Espadas G; Mancuso FM; Bozzola M; Malpasso G; Valentini V; Palladini G; Orrù S; Ferraro G; Milani P; Perlini S; Salvatore F; Merlini G; Lavatelli F
Sci Rep; 2017 Nov; 7(1):15661. PubMed ID: 29142197
[TBL] [Abstract][Full Text] [Related]
8. Receptor-mediated endocytosis of immunoglobulin light chains by renal proximal tubule cells.
Batuman V; Guan S
Am J Physiol; 1997 Apr; 272(4 Pt 2):F521-30. PubMed ID: 9140054
[TBL] [Abstract][Full Text] [Related]
9. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.
Clos AL; Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Jackson GR; Kelly B; Beachkofsky TM; Kayed R
Br J Dermatol; 2011 Dec; 165(6):1349-54. PubMed ID: 21729025
[TBL] [Abstract][Full Text] [Related]
10. A Substantial Structural Conversion of the Native Monomer Leads to in-Register Parallel Amyloid Fibril Formation in Light-Chain Amyloidosis.
Lecoq L; Wiegand T; Rodriguez-Alvarez FJ; Cadalbert R; Herrera GA; Del Pozo-Yauner L; Meier BH; Böckmann A
Chembiochem; 2019 Apr; 20(8):1027-1031. PubMed ID: 30565364
[TBL] [Abstract][Full Text] [Related]
11. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.
Lavatelli F; Imperlini E; Orrù S; Rognoni P; Sarnataro D; Palladini G; Malpasso G; Soriano ME; Di Fonzo A; Valentini V; Gnecchi M; Perlini S; Salvatore F; Merlini G
FASEB J; 2015 Nov; 29(11):4614-28. PubMed ID: 26220173
[TBL] [Abstract][Full Text] [Related]
12. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
13. Review: immunoglobulin light chain amyloidosis--the archetype of structural and pathogenic variability.
Bellotti V; Mangione P; Merlini G
J Struct Biol; 2000 Jun; 130(2-3):280-9. PubMed ID: 10940232
[TBL] [Abstract][Full Text] [Related]
14. Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis.
Brancaccio D; Ghiggeri GM; Braidotti P; Garberi A; Gallieni M; Bellotti V; Zoni U; Gusmano R; Coggi G
J Am Soc Nephrol; 1995 Oct; 6(4):1262-70. PubMed ID: 8589295
[TBL] [Abstract][Full Text] [Related]
15. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
[TBL] [Abstract][Full Text] [Related]
16. Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains.
Klimtchuk ES; Peterle D; Bullitt E; Connors LH; Engen JR; Gursky O
Amyloid; 2023 Dec; 30(4):364-378. PubMed ID: 37216473
[TBL] [Abstract][Full Text] [Related]
17. Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains.
Davern S; Murphy CL; O'Neill H; Wall JS; Weiss DT; Solomon A
Biochim Biophys Acta; 2011 Jan; 1812(1):32-40. PubMed ID: 20692337
[TBL] [Abstract][Full Text] [Related]
18. Splenic plasma cells can serve as a source of amyloidogenic light chains.
Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
[TBL] [Abstract][Full Text] [Related]
19. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils.
Ren R; Hong Z; Gong H; Laporte K; Skinner M; Seldin DC; Costello CE; Connors LH; Trinkaus-Randall V
J Biol Chem; 2010 Nov; 285(48):37672-82. PubMed ID: 20870723
[TBL] [Abstract][Full Text] [Related]
20. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains.
Maritan M; Romeo M; Oberti L; Sormanni P; Tasaki M; Russo R; Ambrosetti A; Motta P; Rognoni P; Mazzini G; Barbiroli A; Palladini G; Vendruscolo M; Diomede L; Bolognesi M; Merlini G; Lavatelli F; Ricagno S
J Mol Biol; 2020 Feb; 432(4):845-860. PubMed ID: 31874151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
